A snakebit biotech receives second CRL for reformulated pain med, potentially putting the kibosh on its chances
Fortress Biotech’s small cap company Avenue Therapeutics has run into another roadblock at the FDA, and this time it may prove to be a TKO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
